Status:

UNKNOWN

Penguin Cold Caps in the Prevention of Hair Loss in Breast Cancer Patients

Lead Sponsor:

Providence Health & Services

Collaborating Sponsors:

Medical Specialties of California

Conditions:

Breast Cancer

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The goal of this study is to estimate the efficacy of Penguin cold caps in preventing or reducing hair loss in patients receiving (neo)adjuvant chemotherapy (one of four common regimens) for early sta...

Detailed Description

This will be a phase II prospective, open label, non-randomized study conducted to determine the safety and efficacy of Penguin TM cold cap system in preventing or reducing chemotherapy-induced alopec...

Eligibility Criteria

Inclusion

  • At least ≥ 18 years of age
  • Diagnosis of stage I-III breast cancer for whom neoadjuvant or adjuvant cytotoxic chemotherapy (ACT/HP, TCH/P, TC, or T/H) is planned.
  • Willing and able to provide informed consent.
  • Availability of caretaker(s) to accompany participant and facilitate cold-cap placement/exchanges using the recommended technique.
  • Women of childbearing potential must use acceptable measures to avoid becoming pregnant during study period and for 30 days after last dose of chemotherapy.

Exclusion

  • Pre-existing alopecia (Dean's scale ≥ 1)
  • Another malignancy that required active treatment with systemic chemotherapy within 2 years of study recruitment.
  • Prior radiotherapy treatment involving head.
  • Pre-existing chronic severe headaches or migraines.
  • Skin conditions that in the opinion of PI would be at risk of worsening with study.
  • Cold sensitivity or cold agglutinin disease
  • Cryoglobulinemia
  • Cryofibrogenemia
  • History of current evidence of any condition, therapy or abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, such that trial participation is not in the best interest of the subject.

Key Trial Info

Start Date :

August 24 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2023

Estimated Enrollment :

9 Patients enrolled

Trial Details

Trial ID

NCT03289364

Start Date

August 24 2017

End Date

January 1 2023

Last Update

September 16 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Providence Cancer Center

Portland, Oregon, United States, 97213